AstraZeneca Pharma India (NSE:ASTRAZEN) E10: ₹41.25 (As of Mar. 2026)


NSE:ASTRAZEN AstraZeneca Pharma India Ltd NSE:ASTRAZEN
92 GF Score
Price ₹8,391.00
GF Value ₹10,868.58
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is AstraZeneca Pharma India E10?

AstraZeneca Pharma India NSE:ASTRAZEN -0.60% 92 E10 is ₹41.25 as of Mar. 2026. GuruFocus rates NSE:ASTRAZEN with a GF Score™ of 92/100 and a GF Value™ of ₹10,868.58 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

AstraZeneca Pharma India's adjusted earnings per share data for the three months ended in Mar. 2026 was ₹17.950. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹41.25 for the trailing ten years ended in Mar. 2026.

During the past 12 months, AstraZeneca Pharma India's average E10 Growth Rate was 26.60% per year. During the past 3 years, the average E10 Growth Rate was 30.70% per year. During the past 5 years, the average E10 Growth Rate was 60.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of AstraZeneca Pharma India was 88.00% per year. The lowest was 30.70% per year. And the median was 62.00% per year.

As of today (2026-06-26), AstraZeneca Pharma India's current stock price is ₹8391.00. AstraZeneca Pharma India's E10 for the quarter that ended in Mar. 2026 was ₹41.25. AstraZeneca Pharma India's Shiller PE Ratio of today is 203.42.

During the past 13 years, the highest Shiller PE Ratio of AstraZeneca Pharma India was 5811.62. The lowest was 171.05. And the median was 246.87.


AstraZeneca Pharma India  (NSE:ASTRAZEN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

AstraZeneca Pharma India's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=8391.00/41.25
=203.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of AstraZeneca Pharma India was 5811.62. The lowest was 171.05. And the median was 246.87.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


AstraZeneca Pharma India E10 Related Terms


AstraZeneca Pharma India E10 Historical Data

* Premium members only.

The historical data trend for AstraZeneca Pharma India's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Pharma India E10 Chart

AstraZeneca Pharma India Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.65 18.50 25.83 32.56 41.25

AstraZeneca Pharma India Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.56 35.23 38.18 39.30 41.25

NSE:ASTRAZEN vs ZTS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca Pharma India Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca Pharma India's Shiller PE Ratio falls into.


NSE:ASTRAZEN
92GF Score
AstraZeneca Pharma India Ltd NSE:ASTRAZEN
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Pharma India E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AstraZeneca Pharma India's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=17.95/164.2724*164.2724
=17.950

Current CPI (Mar. 2026) = 164.2724.

AstraZeneca Pharma India Quarterly Data

per share eps CPI Adj_EPS
201606 5.040 105.961 7.814
201609 0.320 105.961 0.496
201612 6.480 105.196 10.119
201703 -3.850 105.196 -6.012
201706 2.320 107.109 3.558
201709 10.950 109.021 16.499
201712 -4.140 109.404 -6.216
201803 1.320 109.786 1.975
201806 2.580 111.317 3.807
201809 3.650 115.142 5.207
201812 11.640 115.142 16.607
201903 3.950 118.202 5.490
201906 8.610 120.880 11.701
201909 5.770 123.175 7.695
201912 10.680 126.235 13.898
202003 2.850 124.705 3.754
202006 7.450 127.000 9.636
202009 10.640 130.118 13.433
202012 8.420 130.889 10.568
202103 10.890 131.771 13.576
202106 4.100 134.084 5.023
202109 4.780 135.847 5.780
202112 4.570 138.161 5.434
202203 11.160 138.822 13.206
202206 8.060 142.347 9.301
202209 13.030 144.661 14.796
202212 11.720 145.763 13.208
202303 6.890 146.865 7.707
202306 21.540 150.280 23.546
202309 20.950 151.492 22.717
202312 6.320 152.924 6.789
202403 15.790 153.035 16.950
202406 -4.720 155.789 -4.977
202409 15.370 157.882 15.992
202412 12.340 158.323 12.804
202503 23.300 157.552 24.294
202506 22.330 159.755 22.961
202509 21.690 162.289 21.955
202512 13.040 163.281 13.119
202603 17.950 164.272 17.950

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹41.25 mean?
AstraZeneca Pharma India (NSE:ASTRAZEN) has a E10 of ₹41.25 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on AstraZeneca Pharma India and its competitors.
Is AstraZeneca Pharma India's E10 too high?
AstraZeneca Pharma India's current E10 is ₹41.25. Overall, AstraZeneca Pharma India has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's E10 compare to ZTS?
AstraZeneca Pharma India's E10 of ₹41.25 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on AstraZeneca Pharma India and its competitors. AstraZeneca Pharma India's current E10 is ₹41.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹10,868.58, compared to a current price of ₹8,391.00 — trading 22.8% below its estimated fair value. The current E10 is ₹41.25. AstraZeneca Pharma India's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current E10 is ₹41.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued. The current stock price of ₹8,391.00 is trading 22.8% below its estimated GF Value™ of ₹10,868.58. GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.

Key valuation signals for NSE:ASTRAZEN:

  • E10: ₹41.25
  • GF Value™: ₹10,868.58 vs. price of ₹8,391.00 (22.8% below fair value)
  • GF Score™: 92/100 with 4 warning signs

No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Pharma India Business Description

Other Exchanges 506820:India
Address Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
92GF Score

Get the complete analysis for NSE:ASTRAZEN

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹8,391.00
Price
₹10,868.58
GF Value